Literature DB >> 27624958

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.

Ryan K Shields1,2,3, Brian A Potoski1,4,2, Ghady Haidar1, Binghua Hao3, Yohei Doi1, Liang Chen5, Ellen G Press1, Barry N Kreiswirth5, Cornelius J Clancy1,3,6, M Hong Nguyen1,2,3.   

Abstract

Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.

Entities:  

Keywords:  Klebsiella pneumoniae carbapenemase; carbapenem-resistant Enterobacteriaceae; ceftazidime-avibactam resistance

Mesh：

Substances：

Year:  2016        PMID： 27624958      PMCID： PMC5146720          DOI： 10.1093/cid/ciw636

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

1.  Development of a set of multiplex PCR assays for the detection of genes encoding important beta-lactamases in Enterobacteriaceae.

Authors:  Caroline Dallenne; Anaelle Da Costa; Dominique Decré; Christine Favier; Guillaume Arlet
Journal:  J Antimicrob Chemother       Date:  2010-01-12       Impact factor: 5.790

Review 2.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury.

Authors:  Paul M Palevsky; Kathleen D Liu; Patrick D Brophy; Lakhmir S Chawla; Chirag R Parikh; Charuhas V Thakar; Ashita J Tolwani; Sushrut S Waikar; Steven D Weisbord
Journal:  Am J Kidney Dis       Date:  2013-03-15       Impact factor: 8.860

3.  Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Ryan K Shields; Cornelius J Clancy; Ellen G Press; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients.

Authors:  C J Clancy; L Chen; R K Shields; Y Zhao; S Cheng; K D Chavda; B Hao; J H Hong; Y Doi; E J Kwak; F P Silveira; R Abdel-Massih; T Bogdanovich; A Humar; D S Perlin; B N Kreiswirth; M Hong Nguyen
Journal:  Am J Transplant       Date:  2013-09-06       Impact factor: 8.086

5.  In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase.

Authors:  David M Livermore; Marina Warner; Dorota Jamrozy; Shazad Mushtaq; Wright W Nichols; Nazim Mustafa; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

6.  Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing Klebsiella pneumoniae may predict responses to carbapenem-colistin combination therapy among patients with bacteremia.

Authors:  Ryan K Shields; M Hong Nguyen; Brian A Potoski; Ellen G Press; Liang Chen; Barry N Kreiswirth; Lloyd G Clarke; Gregory A Eschenauer; Cornelius J Clancy
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

7.  Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae.

Authors:  Ryan K Shields; Cornelius J Clancy; Binghua Hao; Liang Chen; Ellen G Press; Nicole M Iovine; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

8.  First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.

Authors:  Romney M Humphries; Shangxin Yang; Peera Hemarajata; Kevin W Ward; Janet A Hindler; Shelley A Miller; Aric Gregson
Journal:  Antimicrob Agents Chemother       Date:  2015-07-20       Impact factor: 5.191

Review 9.  Treating infections caused by carbapenemase-producing Enterobacteriaceae.

Authors:  L S Tzouvelekis; A Markogiannakis; E Piperaki; M Souli; G L Daikos
Journal:  Clin Microbiol Infect       Date:  2014-07-12       Impact factor: 8.067
  9 in total
  121 in total

1.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

2.  Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient.

Authors:  Vasilios Athans; Elizabeth A Neuner; Habiba Hassouna; Sandra S Richter; George Keller; Mariana Castanheira; Kyle D Brizendine; Amy J Mathers
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 3.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

4.  Resistance to Ceftazidime-Avibactam Is Due to Transposition of KPC in a Porin-Deficient Strain of Klebsiella pneumoniae with Increased Efflux Activity.

Authors:  Kirk Nelson; Peera Hemarajata; Dongxu Sun; Debora Rubio-Aparicio; Ruslan Tsivkovski; Shangxin Yang; Robert Sebra; Andrew Kasarskis; Hoan Nguyen; Blake M Hanson; Shana Leopold; George Weinstock; Olga Lomovskaya; Romney M Humphries
Journal:  Antimicrob Agents Chemother       Date:  2017-09-22       Impact factor: 5.191

5.  Carbapenem-resistant Enterobacteriaceae: What we know and what we need to know.

Authors:  David van Duin
Journal:  Virulence       Date:  2017-04-12       Impact factor: 5.882

6.  Treatment and mortality of Klebslella pneumoniae infections in critically ill patients: should we do and predict them better?

Authors:  Matteo Bassetti; Mura Akova; Mario Tumbarello
Journal:  Intensive Care Med       Date:  2018-09-28       Impact factor: 17.440

Review 7.  [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].

Authors:  Alexander Mischnik; Christoph Lübbert; Nico T Mutters
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

8.  Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study.

Authors:  Maddalena Giannella; Elena Graziano; Lorenzo Marconi; Nicolo Girometti; Michele Bartoletti; Sara Tedeschi; Fabio Tumietto; Francesco Cristini; Simone Ambretti; Andrea Berlingeri; Russell E Lewis; Pierluigi Viale
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-01       Impact factor: 3.267

9.  Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections.

Authors:  Renee Ackley; Danya Roshdy; Jacqueline Meredith; Sarah Minor; William E Anderson; Gerald A Capraro; Christopher Polk
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

Review 10.  Pharmacological aspects and spectrum of action of ceftazidime-avibactam: a systematic review.

Authors:  Felipe Francisco Tuon; Jaime L Rocha; Marcelo R Formigoni-Pinto
Journal:  Infection       Date:  2017-11-07       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.